Evidence map›Paper›PMID 22623658›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2012

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Donna M Barten, Patrizia Fanara, Cathy Andorfer, Nina Hoque, P Y Anne Wong, Kristofor H Husted, Gregory W Cadelina, Lynn B Decarr, Ling Yang, Victoria Liu and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effect of Vitamin E on Transcriptomic Alterations in Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
  10. Article
  11. The Role of Axonal Transport in Glaucoma.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Article
  19. Review
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Donna M BartenNeuroscience Drug Discovery, Bristol-Myers Squibb, Wallingford, Connecticut 06492, USA. donna.barten@bms.com
Patrizia Fanara
Cathy Andorfer
Nina Hoque
P Y Anne Wong
Kristofor H Husted
Gregory W Cadelina
Lynn B Decarr
Ling Yang
Victoria Liu
Chancy Fessler
Joan Protassio
Timothy Riff
Holly Turner
Christopher G Janus
Sethu Sankaranarayanan
Craig Polson
Jere E Meredith
Gemma Gray
Amanda Hanna
Richard E Olson
Soong-Hoon Kim
Gregory D Vite
Francis Y Lee
Charles F Albright
Bristol-Myers Squibb (United States) · USKineMed (United States) · USJacksonville College · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tau is a microtubule (MT)-stabilizing protein that is altered in Alzheimer's disease (AD) and other tauopathies. It is hypothesized that the hyperphosphorylated, conformationally altered, and multimeric forms of tau lead to a disruption of MT stability; however, direct evidence is lacking in vivo. In this study, an in vivo stable isotope-mass spectrometric technique was used to measure the turnover, or dynamicity, of MTs in brains of living animals. We demonstrated an age-dependent increase in MT dynamics in two different tau transgenic mouse models, 3xTg and rTg4510. MT hyperdynamicity was dependent on tau expression, since a reduction of transgene expression with doxycycline reversed the MT changes. Treatment of rTg4510 mice with the epothilone, BMS-241027, also restored MT dynamics to baseline levels. In addition, MT stabilization with BMS-241027 had beneficial effects on Morris water maze deficits, tau pathology, and neurodegeneration. Interestingly, pathological and functional benefits of BMS-241027 were observed at doses that only partially reversed MT hyperdynamicity. Together, these data suggest that tau-mediated loss of MT stability may contribute to disease progression and that very low doses of BMS-241027 may be useful in the treatment of AD and other tauopathies.

Indexed as

AnimalsBrainCognition DisordersDisease Models, AnimalDose-Response Relationship, DrugDoxycyclineDrug Evaluation, PreclinicalEpothilonesFemaleHippocampusMaleMaze LearningMiceMice, Inbred C57BLMice, TransgenicMicrotubulesdesoxyepothilone BDoxycyclineEpothilonestau ProteinsTubulin Modulators

Identifiers

PMID22623658
PMCPMC6622320
OpenAlexW2048839541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.